Document is current
Any future updates will be listed below
-
Authors
Hermann, Sandra https://orcid.org/0000-0002-7959-9559
Palmowski, Andriko https://orcid.org/0000-0002-3456-0597
Hermann, Kay Geert A. https://orcid.org/0000-0001-6142-3814
Muche, Burkhard https://orcid.org/0000-0003-4104-5080
Léprêtre, Nadége https://orcid.org/0009-0002-2301-6788
Alexander, Tobias https://orcid.org/0000-0003-1193-0097
Boyadzhieva, Zhivana https://orcid.org/0000-0002-6708-0688
Krönke, Gerhard https://orcid.org/0000-0002-7566-4325
Hoff, Paula https://orcid.org/0000-0001-7494-0845
Wiebe, Edgar https://orcid.org/0000-0002-3600-0788
Buttgereit, Frank https://orcid.org/0000-0003-2534-550X
-
Funding
Funding for this research was provided by:
AbbVie Deutschland (AbbVie Deutschland)
Almirall (Almirall)
Amgen (Amgen)
Biogen (Biogen)
Bristol-Myers Squibb (Bristol-Myers Squibb)
Chugai (Chugai)
Galápagos (Galápagos)
Generic Assays (Generic Assays)
GlaxoSmithKline (GlaxoSmithKline)
Hexal AG (Hexal AG)
Horizon Therapeutics (Horizon Therapeutics)
Eli Lilly and Company (Eli Lilly and Company)
Medac (Medac)
Mundipharma (Mundipharma)
Novartis Pharma (Novartis Pharma)
Pfizer (Pfizer)
Roche Deutschland (Roche Deutschland)
Sanofi Genzyme (Sanofi Genzyme)
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 27 June 2024
First Online: 29 July 2024
Declarations
:
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Specific disclosures are as follows: AP – Participation in a Data Safety Monitoring Board for Novartis; KGAH – Consulting fees from AbbVie, MSD, and Novartis; co-founder of BerlinFlame GmbH; EW – Honoraria from Novartis for lectures; PH – Honoraria from UCB and Stada Germany for lectures; FB – Support for attending meetings from AbbVie and Pfizer; SH – Honoraria from AbbVie for lectures. NL, GK, BZ, TA, BM declare no specific conflicts of interest at all.
